Evidence map›Paper›PMID 42724559›Full record

ArticleEFSA journal. European Food Safety Authority2026

Setting of an import tolerance for fenazaquin in teas.

European Food Safety Authority (EFSA), Giulia Bellisai, Giovanni Bernasconi, Irene Castellan, Monica Del Aguila, Lucien Ferreira, Renata Leuschner, Andrea Mioč, Marta Szot, Manuela Tiramani and 1 more

Abstract read
In one paragraph

Article in EFSA journal. European Food Safety Authority, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

European Food Safety Authority (EFSA)
Giulia Bellisai
Giovanni Bernasconi
Irene Castellan
Monica Del Aguila
Lucien Ferreira
Renata Leuschner
Andrea Mioč
Marta Szot
Manuela Tiramani
Alessia Verani

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In accordance with Article 6 of Regulation (EC) No 396/2005, the applicant Gowan Crop Protection Limited submitted a request to the competent national authority in Germany to set an import tolerance for the active substance fenazaquin in teas imported from India. The results of the four new residue trials submitted in support of the request, together with those previously assessed during the maximum residue level (MRL) review for the same import tolerance, on the basis of which a tentative MRL of 9 mg/kg was set, are sufficient to derive an MRL for teas at the same level. The enforcement analytical method and its independent laboratory validation (ILV) submitted were found to be adequate to control fenazaquin residues in the commodity under consideration at the validated limit of quantification (LOQ) of 0.01 mg/kg. Based on the risk assessment results, EFSA concluded that the short-term and long-term intake of residues of fenazaquin and its toxicologically relevant plant metabolite 2-(4-tert-butylphenyl) ethanol (TBPE) resulting from the use of fenazaquin on teas imported from India according to the reported agricultural practice is unlikely to present a risk to consumer health. The consumer risk assessment for TBPE is indicative only, due to uncertainties related to missing residue data for this metabolite in commodities covered by EU-implemented Codex maximum residue limit (CXLs). Risk managers may consider either confirming the existing MRL of 9 mg/kg or lowering the value to 3 mg/kg, in line with the MRL currently in force in the country of origin.

Indexed as

consumer risk assessmentFenazaquinimport toleranceMRLpesticideTBPEteas

Identifiers

PMID42724559
PMCPMC13559795

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.